POLYAMINES occur naturally in all living organisms, and are intimately associated with growth whether normal or neoplastic (Ham, 1964; Duffy et al., 1971) . Raised levels of polyamines are associated with cell growth, such as embryogenesis, heptatic regeneration, and lactation, as well as solid and haematological tumours (Hospattankar et al., 1980) . Their existence has been known for several years, but it is their function as growth promoters that has most recently raised interest as to their possible association with neoplastic processes (Russell, 1973) . The findings, first by Russell (1971) and then others (Harik & Sutton, 1979; Marton et al., 1973) that polyamine levels are raised in the urine and sera of cancer patients, have singled them out as potential biochemical markers for cancer detection. The fluctuations in levels of polyamines found during malignancy reflect pathological changes, and variations in their concentrations may be used to determine a patient's response to radiation or chemotherapy (Durie et al., 1977; Russell et al., 1975) . The presence of polyamines and their regulating enzymes during the cancer process appear to be intimately related. This is further supported by the work of O'Brien & Diamond (1977) who showed that increased levels of polyamines were intrinsic to tumour promotion in vitro, and suggested that normal and transformed cells differ in their control of polyamine biosynthesis.
Among the naturally occurring polyamines, putrescine, spermine and spermidine are best known. Their increase during growth and differentiation usually precede increases in RNA, DNA and protein synthesis. Putrescine, in elevated amounts, appears to be related to the growth fraction of a tumour and elevated levels of spermidine to the cell-loss factor.
The fact that polyamines can influence cancer therapy has already been shown with hyperthermia, where their presence increases heat-mediated cell death (Ben Hur & Rikils, 1979; Gerner & Russell, 1977) . It seemed relevant and pertinent, therefore, to ask whether the polyamines could likewise modify the action of antineoplastic chemotherapy agents. cisDiamminedichloroplatinum was chosen for this study, a drug commonly used in clinical practice for the treatment of various testicular and bladder carcinomas, as well as tumours of the head and neck (Heydron, 1979 6h exposure at 20 juM, a clinically relevant dosage. Fig. 2 compares the effect on cell survival of a 2h exposure to various concentrations of cis-DDP, with and without 30 mm putrescine. The presence of the polyamine considerably reduces the cytotoxicity of the cis-DDP, at a concentration of putrescine that was of itself non-toxic to the cells.
The effect of two concentrations of putrescine on the survival of cells exposed to cis-DDP at a fixed concentration of 20 tM for various periods of time is shown in Fig. 3 . Protection against platinum toxicity is evident for both concentrations of polyamine (10 and 30 mM) for all periods tested, the higher concentration of putrescine being the more effective. The data in Fig. 4 show how the temporal sequence of the application of putrescine and cis-DDP influences cell survival. Cells Fig. 5 shows the progressive decline in cell survival when cells are exposed to increasing levels of spermine for a 4h period in complete growth medium containing 10% FCS. The same is true of spermidine, though the data are not shown in the Figure. This toxicity is due largely to the presence in calf serum of amine oxidase, which oxidizes spermine to a toxic aminoaldehyde (Tabor et al., 1964) . This toxicity can be avoided if the exposure of the cells to the polyamine is carried out in serumfree medium. This is illustrated for both spermine and spermidine in the upper curves of Fig. 5 . Fig. 6 shows the survival of cells exposed for 2 h to graded concentrations of cis-DDP in the presence or absence of spermine. These treatments were carried out in serum-free medium to avoid the toxicity referred to above. It is clear that spermine, like putrescine, affords substantial protection against cell killing by cis-DDP. DISCUSSION These results show that the presence of the polyamines putrescine and spermine can significantly reduce the cytotoxicity of the commonly used chemotherapy agent cis-DDP. This holds true for high or low drug concentrations, as well as extended exposures, which may be particularly relevant to cis-DDP, which is known to have a slow clearance time from tissues. These data may have important implications for clinical chemotherapy since it is well established that polyamine levels may be significantly higher during tumour growth and regression (spermidine levels rise significantly with tumour-cell kill).
Although it was shown by Heby & Russell (1973) that methotrexate, cytosine arabinoside and 5 azacytidine reduced polyamine levels in the spleens of leukaemic mice, their levels once again started to rise significantly after about 8 days of therapy. Chemotherapeutic drugs are known to interfere with DNA, RNA, and protein synthesis. In spite of this, there is a lack of data relating increased polyamine levels with chemotherapeutic drug toxicity. This can assume considerable importance in the light of recent evidence by Rupniak et al. (1980) , who have shown that transformed cells lacked polyamine growthregulatory mechanisms, and may not be subject to the normal restraints of polyamine biosynthesis. Traditional studies of in vitro drug toxicities may not then give a complete picture of drug action, since polyamines are absent.
The mechanism of the interaction of the polyamines with cis-DDP is not clear at present, but a number of hypotheses can be advanced. cis-DDP is generally classified as an alkylating agent whose cytotoxic effects results from interaction with DNA or its constituents (Douple & Richmond, 1979) and it is possible that polyamines may alter this effect since they are thought to stabilize secondary structures of nucleic acids. Alternatively, polyamines are thought to exert cell-membrane effects (Schindler et al., 1980) and possibly this could influence drug transport. This explanation is less likely, however, since similar studies done concurrently with another chemotherapeutic drug, Bleomycin, (unpublished) showed no effect of polyamines on drug toxicity. Another possibility may be that elevated levels of polyamines could affect overall cell kinetics and alter cell cycle distribution.
Our results raise questions as to the effects of polyamines in combination with some chemotherapeutic agents, since their levels increase during a course of chemotherapy, and may adversely affect the therapeutic ratio. The fact that this is seen with cis-DDP warrants further investigation with other chemotherapeutic agents.
